Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD-Reference-Cited by-同舟云学术

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD

Published:2013-03-27 Issue:5 Volume:161 Page:659-666
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Takahashi Koichi,Kantarjian Hagop¹,Pemmaraju Naveen¹,Andreeff Michael¹,Borthakur Gautam¹,Faderl Stefan¹,Garcia-Manero Guillermo¹,Pierce Sherry¹,Luthra Rajyalakshmi²,Cardenas-Turanzas Marylou¹,Estrov Zeev¹,Ravandi Farhad¹,Cortes Jorge¹

Affiliation:

1. Department of Leukemia; MD Anderson Cancer Center; The University of Texas; Houston; TX; USA

2. Department of Hematopathology; MD Anderson Cancer Center; The University of Texas; Houston; TX; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12299/fullpdf

Reference27 articles.

1. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia;Cheson;Journal of Clinical Oncology,2003

2. AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study;Cortes;Blood,2009

3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3;Fischer;Journal of Clinical Oncology,2010

4. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm;Frohling;Blood,2002

5. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia;Gale;Blood,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study;Journal of Internal Medicine;2023-10-29

2. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules;Statistics in Medicine;2021-06-07

3. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients;Leukemia Research;2021-02

4. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients;Clinical Lymphoma Myeloma and Leukemia;2018-08

5. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML);Leukemia Research;2018-04